- BNF:
- 8.3.4.2
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- August 2014
Comments
RED1,2,3: NICE TA316: enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with docetaxel-containing regimen.
RED1,2,3: NICE TA377 - for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. (Decision date - February 2016)
RED1,2,3: NICE TA712 - for treating hormone-sensitive metastatic prostate
cancer (Decision date - August 2021)
DO NOT PRESCRIBE (DNP)6: NICE TA580 - for hormone-relapsed non-metastatic prostate cancer. (Decision date - June 2019)
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again